Skip directly to: Navigation for this section | Main page content

Human Development Graduate Group

  • Photo: Alternate description of photo goes here

    Randi Hagerman

    Distinguished Professor of Pediatrics, endowed chair in Fragile X Research, Medical Director of the MIND Institute and Director of the Clinical Trials Program at the MIND
    At UCD since: 2000
    Interests: Biological, Cognitive, Social-Emotional, Family, Health & Mental Health
    Life Phases: Early Childhood, Middle Childhood, Adolescence, Emerging Adulthood, Adulthood

  • Research Interests
    Dr. Hagerman has more than 20 years of experience in the field of neurodevelopmental disorders and fragile X syndrome - the most common inherited cause of intellectual disability and autism. Her research focuses on targeted treatments for neurodevelopmental disorders including fragile X syndrome and premutation disorders including the fragile X-associated tremor ataxia syndrome (FXTAS) and international screening for fragile X syndrome and international treatment studies and training endeavors.

    Selected Publications

    Kover ST, McDuffie AS, Hagerman RJ, Abbeduto L. (2013) Receptive Vocabulary in Boys with Autism Spectrum Disorder: Cross-sectional Developmental Trajectories. J Autism Dev Disord 43(11):2696-709.  

    Leigh MJ, Nguyen DV, Mu Y, Winarni TI, Schneider A, Chechi T, Polussa J, Doucet P, Tassone F, Rivera SM, Hessl D, Hagerman RJ. (2013) A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile X syndrome. J Dev Behav Pediatr 34(3):147-155.

    Wang JY, Hagerman RJ, Rivera SM. (2013) A multimodal imaging analysis of subcortical gray matter in fragile X premutation carriers. Mov Disord 28(9):1278-84.

    Au J, Akins R, Berkoqitz-Sutherland L, Tang HT, Chen Y, Boyd A, Tassone F, Nguyen D, Hagerman R. (2013) Prevalence and risk of migraine headaches in adult fragile X premutation carriers. Clin Genet. Feb 1. doi: 10.1111/cge.12109 [Epub ahead of print].

    Schneider A, Leigh MJ, Adams P, Nanakul R, Chechi T, Olichney J, Hagerman R, Hessl D. (2013) Electrocortical changes associated with minocycline treatment in fragile X syndrome. J Psychopharm 27(10):956-963. doi: 10.1177/0269881113494105.

    Schneider A, Ligsay A, Hagerman RJ. (2013) Fragile X syndrome: An aging perspective. Dev Disabil Res Rev 18(1):68-74.

    Dziembowska M, Pretto DI, Janusz A, Kaczmarek L, Leigh MJ, Gabriel N, Durbin-Johnson B, Hagerman RJ, Tassone F. (2013) High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. Am J Med Genet A 161A(8):1897-903.

    Hagerman R, Hagerman P.  (2013) Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome (FXTAS). Lancet Neurol 12(8):786-98.

    Wang JY, Hessl D, Schneider A, Tassone F, Hagerman RJ, Rivera SM. (2013) Fragile X-associated tremor/ataxia syndrome (FXTAS): influence of the FMR1 gene on motor fiber tracts in males with normal and premutation alleles. JAMA Neurol 70(8):1022-9.

    Basuta K, Lozano R, Schneider A, Yrigollen CM, Hessl D, Hagerman RJ, Tassone F. (2014) A family with two female siblings with compound heterozygous FMR1 premutation alleles. Clin Genet 85(5):458-63.

    Pretto DI, Hunsaker MR, Cunningham CL, Hagerman RJ, Greco CM, Hall DA, Noctor SC, Hagerman PJ, Tassone F. (2013) Intranuclear inclusion in a fragile X mosaic male. Transl Neurodegener 2(1):10.

    Yang J-C, Simon C, Niu Y-Q, Bogost M, Schneider A, Tassone F, Seritan A, Grigsby J, Hagerman PJ, Hagerman RJ, Olichney JM. (2013) Phenotypes of hypofrontality in older female fragile X premutation carriers. Ann Neurol 74:275-283.

    Winarni TI, Agustini U, Mundhofir FEP, Hagerman RJ, Faradz SMH. (2013) Fragile X syndrome: Clinical, cytogenetic and molecular screening among autism spectrum disorder children in Indonesia. Clin Genet 84(6):577-80.

    McDuffie A, Thurman AJ, Hagerman RJ, Abbeduto L. (2013) Symptoms of autism in males with fragile X syndrome: A comparison to nonsyndromic ASD using current ADI-R scores. JADD. doi:10.1007/s10803-013-2013-6.

    Jacquemont S, Berry-Kravis E, Hagerman R, von Raison F, Gasparini F, Apostol G, Ufer M, Des Portes V, Gomez-Mancilla B. (2014) Development of mavoglurant and its potential for the treatment of fragile X syndrome. Expert Opin Investig Drugs 23(1):125-34.

    Jacquemont S, Berry-Kravis E, Hagerman R, von Raison F, Gasparini F, Apostol G, Ufer M, Des Portes V, Gomez-Mancilla B. (2014) The challenges of clinical trials in fragile X syndrome. Psycopharmacology 231:1237-1250. doi 10.1007/s00213-013-3289-0.

    Besterman AD, Wilke SA, Mulligan TE, Allison SC, Hagerman R, Seritan AL, Bourgeois JA. (2014)  Towards an understanding of neuropsychiatric manifestations in fragile X premutation carriers. Future Neurology. 9(2): 227-239.

    Renda MM, Voigt RG, Babovic-Vuksanovic D, Highsmith WE, Vinson SS, Sadowski CM, Hagerman RJ. (2014) Neurodevelopmental disabilities in children with intermediate and premutation range fragile X cytosine-guanine expansions. J Child Neurol 29(3):326-30.

    Pretto DI, Mendoza-Morales G, Lo J, Cao R, Hadd A, Latham GJ, Durbin-Johnson B, Hagerman R, Tassone F. (2014) CGG allele size somatic mosaicism and methylation in FMR1 premutation alleles. J Med Genet. Mar 3. doi: 10.1136/jmedgenet-2013-10201. [Epub ahead of print].

    Hare EB, Hagerman RJ, Lozano R. (2014) Targeted treatments in fragile X syndrome. Expert Opinion. Informa Healthcare. doi: 10.1517/21678707.2014.903795. [Epub ahead of print].

    Kover ST, Haebig E, Oakes A, McDuffie A, Hagerman RJ, Abbeduto L. (2014) Sentence comprehension in boys with autism spectrum disorder. Am J Speech Lang Pathol. doi: 10.1044/2014_AJSLP-13-0073. [Epub ahead of print].

    Niu YQ, Yang JC, Hall DA, Leehey MA, Tassone F, Olichney JM, Hagerman RJ, Zhang L. (2014) Parkinsonism in fragile X-associated tremor/ataxia syndrome (FXTAS): revisited. Parkinsonism Relat Disord 20(4):456-9.

    Loesch DZ, Bui MQ, Hammersley E, Schneider A, Sorey E, Stimpson P, Burgess T, Francis D, Slater H, Tassone F, Hagerman RJ, Hessl D. (2014) Psychological status in female carriers of premutation FMR1 allele showing a complex relationship with the size of CGG expansion. Clin Genet. doi: 10.1111/cge.12347 [Epub ahead of print].

    Seritan AL, Nguyen DV, Mu Y, Tassone F, Bourgeois JA, Schneider A, Cogswell JB, Cook KR, Leehey MA, Grigsby J, Olichney JM, Adams PE, Legg W, Zhang L, Hagerman PJ, Hagerman RJ. (2014) Memantine for Fragile X-associated Tremor/Ataxia Syndrome: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 75(3):264-71.

    Pretto DI, Kumar M, Cao Z, Cunningham CL, Durbin-Johnson B, Qi L, Berman R, Noctor SC, Hagerman RJ, Pessah IN, Tassone F. (2014) Reduced excitatory amino acid transporter 1 and metabotropic glutamate receptor 5 expression in the cerebellum of fragile X mental retardation gene 1 premutation carriers with fragile X–associated tremor/ataxia syndrome. Neurobiol Aging 35(5):1189-97.

    Yang JC, Simon C, Schneider A, Seritan AL, Hamilton L, Hagerman PJ, Hagerman RJ, Olichney JM. (2014) Abnormal semantic processing in females with Fragile X-Associated Tremor/ Ataxia Syndrome (FXTAS). Genes Brain Behav 13(2):152-62.

    Thurman AJ, McDuffie A, Hagerman RJ, Abbeduto L. (2014) Psychiatric symptoms in boys with fragile X syndrome: A comparison with nonsyndromic autism spectrum disorder. Res Dev Disabil 35(5):1072-86.

    Seritan AL, Bourgeois JA, Schneider A, Mu Y, Hagerman RJ, Nguyen DV. (2013) Ages of onset of mood and anxiety disorders in fragile X premutation carriers. Current Psychiatry Reviews. Curr Psychiatr Rev 9(1):65-71.

    Seritan AL, Ortigas M, Seritan S, Bourgeois JA, Hagerman RJ. (2013) Psychiatric Disorders associated with FXTAS. Curr Psychiatr Rev. 9(1):59-64.

    Polussa J, Schneider A, Hagerman R. (2014) Molecular Advances Leading to Treatment Implications for Fragile X Premutation Carriers. Brain Disord Ther 3:2.

    Wheeler AC, Bailey DB Jr., Berry-Kravis E, Greenberg J, Losh M, Mailick M, Montserrant M, Olichney J, Rodriguez-Revenga L, Sherman S, Smith L, Summers S, Yang JC, Hagerman R. (2014) Associated features in females with an FMR1 premutation. J Neurodev Disord; 6(1):30 doi: 10.1186/1866-1955-6-30. Epub 2014 Jul 30.

    Yang JC, Chi L, Teichholtz S, Schneider A, Nankul R, Nowacki R, Seritan A, Reed B, DeCarli C, Iraqui VJ, Kutas M, Hagerman PH, Hagerman RJ, Olichney JM. (2014) ERP abnormalities elicited by word repetition in fragile X-associated tremor/ataxia syndrome (FXTAS) and amnestic MCI. Neuropsychologia doi: 10.1016/j.neuropsychologia.08.001. Epub ahead of print.

    Benjamin DP, Mastergeorge AM, McDuffie AS, Kover ST, Hagerman RJ, Abbeduto L. (2014) Effects of labeling and pointing on object gaze in boys with fragile X syndrome: An eye-tracking study. Res Dev Disabil 35(11):2658-2672. doi: 10.1016/j.ridd.2014.06.021. Epub ahead of print.

    Hagerman RJ, Des-Portes V, Gasparini F, Jacquemont S, Gomez-Mancilla B. (2014) Translating molecular advances in fragile X syndrome into therapy: a review. J Clin Psychiatry 75(4):e294-307. doi: 10.4088/JCP.13r08714.